Haemophilia
Hematologic disorder asymptomatically carried by females.
Definition and Causes of Disorder
Haemophilia was first thoroughly analyzed by Friedrich Hopff in 1828. The term originates from the Hellenic words Haima and Philia, the former meaning blood and the latter love. The disesase can either be caused by heredity or random mutation. For an afflicted person blood fails to coagulate when an injury is suffered, thus causing subsequent bleeding to be of an extraordinary length. Fortunately, the disease is rare. It can affect any part of the body where an injury could be had.
Abression becomes facilitated
The surface of the skin belonging to the afflicted is easily bruised. Bruises such as the ones above.
A Young Queen Victoria
The origin of Haemophilia in European Royal Families was due to a random mutation in Queen Victoria's DNA not, like is oft thought, as a result of incest. Though, because Queen Victoria's progeny married among other Royal families it was thus perpetuated in those regal blood lines.
Karyotype of Haemophilia
As you can see Haemophilia is passed through a recessive-x chromosome
Treatment and Research Outlook
What treatment is offered and what reserch is being done to help people with this disorder?
In cases where a family history of haemophilia exists a genetic test is made to diagnose the disorder. Cases of mild haemophilia can go undiagnosed for a decade or more, however, because a bleeding episode might not occur until surgery is performed or an injury suffered. A blood test will provide a result without a doubt.
There does not exists an universal medication for Haemophilia as there three different types of the disorder. Type A, the most common of the three, is treated with Prophylaxis a preventative medicine. Octocag Alfa is used for type A haemophilic bleeding episodes. Abnacag Alfa is used for type B haemophilia.
The European Haemophilia Consortium, the UK's NHS, and America's CDC are all currently conducting research for future treatments. The NHS has had some success with the use of gene theraphy
There does not exists an universal medication for Haemophilia as there three different types of the disorder. Type A, the most common of the three, is treated with Prophylaxis a preventative medicine. Octocag Alfa is used for type A haemophilic bleeding episodes. Abnacag Alfa is used for type B haemophilia.
The European Haemophilia Consortium, the UK's NHS, and America's CDC are all currently conducting research for future treatments. The NHS has had some success with the use of gene theraphy